{
    "clinical_study": {
        "@rank": "68633", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Active Comparator", 
                "description": "Conventional (Rabies and JE Vaccines)"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Experimental", 
                "description": "Accelerated (Rabies and JE Vaccines)"
            }, 
            {
                "arm_group_label": "Group 3", 
                "arm_group_type": "Active Comparator", 
                "description": "Conventional (Rabies Vaccine alone)"
            }, 
            {
                "arm_group_label": "Group 4", 
                "arm_group_type": "Active Comparator", 
                "description": "Conventional (JE Vaccine alone)"
            }
        ], 
        "brief_summary": {
            "textblock": "Establish non-inferiority of the immune response and evaluate the safety and tolerability of\n      Rabies and Japanese Encephalitis (JE) vaccines given concomitantly or alone and according to\n      either of 2 schedules for preexposure prophylaxis."
        }, 
        "brief_title": "Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Rabies", 
            "Japanese Encephalitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Encephalitis", 
                "Encephalitis, Japanese", 
                "Rabies"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Males and females between 18 and 65 years of age (inclusive).\n\n          2. Subjects who have given written consent.\n\n          3. Individuals in good health as per investigator judgement.\n\n        Exclusion Criteria:\n\n          1. If female, pregnancy or unwillingness to practice acceptable contraception.\n\n          2. If female, pregnant or breast-feeding female or any positive/indeterminate pregnancy\n             test.\n\n          3. Contraindication or precaution against Rabies and Japanese Encephalitis vaccination.\n\n          4. Unable to comprehend and to follow all required study procedures for the whole period\n             of the study.\n\n          5. Participating in any other clinical trial 30 days prior to first study visit.\n\n          6. History of previous rabies/rabies immunoglobulin and/or Japanese Encephalitis\n             immunization.\n\n          7. Receiving or planning to receive anti-malarial medications (e.g. Mefloquine) 14 days\n             prior to Day 1 vaccination through Day 43.\n\n          8. Received any other vaccines within 2 weeks prior to enrollment in this study or plan\n             to receive any vaccine within 4 weeks from the study vaccines.\n\n          9. Ever received blood, blood products and/or plasma derivatives or any parenteral\n             immunoglobulin preparation in the past 12 weeks.\n\n         10. Individuals who are part of study personnel or close family members conducting this\n             study.\n\n         11. Body temperature \u226538 degrees Celsius (\u2265 100.4\u00b0 F) within 3 days of intended study\n             vaccination\n\n         12. Plans to travel within the next year to areas where Rabies and/or Japanese\n             Encephalitis vaccine may be considered or offered. This includes but is not limited\n             to India, Asia, Pacific-Rim, African countries."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "660", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01662440", 
            "org_study_id": "V49_23", 
            "secondary_id": "2011-005173-23"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2", 
                    "Group 3"
                ], 
                "intervention_name": "Rabies", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2", 
                    "Group 4"
                ], 
                "intervention_name": "Japanese Encephalitis", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Rabies", 
            "JE", 
            "accelerated schedule"
        ], 
        "lastchanged_date": "November 4, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kinderspitalgasse 15", 
                        "country": "Austria", 
                        "state": "Vienna", 
                        "zip": "A-1090"
                    }, 
                    "name": "Institute of Specific Prophylaxis and Tropical Medicine Center for Pathophysiology, Infectious Diseases and Immunology Medical University of Vienna"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bernhard-Nocht-Strasse 74", 
                        "country": "Germany", 
                        "state": "Hamburg", 
                        "zip": "D-20359"
                    }, 
                    "name": "Bernhard Nocht Institute for Tropical Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "R\u00e4mistrasse 71", 
                        "country": "Switzerland", 
                        "state": "Z\u00fcrich", 
                        "zip": "CH-8006"
                    }, 
                    "name": "The University of Zurich"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Germany", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase III, Multicenter, Observer-blind, Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Concomitantly and/or Separately According to 1 of 2 Different Preexposure Prophylaxis Schedules to Healthy Adult Subjects.", 
        "overall_official": {
            "affiliation": "Novartis Vaccines", 
            "last_name": "Novartis Vaccines and Diagnostics", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Germany: Paul-Ehrlich-Institut", 
                "Austria: Agency for Health and Food Safety", 
                "Switzerland: Swissmedic"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Percentage of subjects with Rabies Virus Neutralizing Antibodies (RVNA) titer \u2265 0.5 IU/mL", 
                "measure": "Non-inferiority of the immune response to Rabies vaccine (administered concomitantly with JE vaccine) accelerated versus conventional schedule.", 
                "safety_issue": "No", 
                "time_frame": "7 days after last active vaccine administration"
            }, 
            {
                "description": "Percentage of subjects with Plaque Reduction Neutralization Test (PRNT50) titer \u2265 1:10", 
                "measure": "Non-inferiority of the immune response to JE vaccine (administered concomitantly with Rabies vaccine) accelerated versus conventional schedule.", 
                "safety_issue": "No", 
                "time_frame": "28 days after last active vaccine administration"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01662440"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Non-inferiority of the immune response of Rabies + JE versus Rabies vaccine as per conventional vaccination schedule.", 
                "measure": "Rabies Virus Neutralizing Antibody Geometric Mean Titer", 
                "safety_issue": "No", 
                "time_frame": "28 days after last active vaccination"
            }, 
            {
                "description": "Non-inferiority of the immune response to JE + Rabies versus JE vaccine as per conventional vaccination schedule.", 
                "measure": "Plaque Reduction Neutralization Test(PRNT50)Geometric Mean Titer", 
                "safety_issue": "No", 
                "time_frame": "28 days after last active vaccination"
            }, 
            {
                "description": "Non-inferiority of the immune response to Rabies + JE accelerated schedule versus Rabies vaccine as per conventional schedule", 
                "measure": "Percentage of subjects with RVNA titer \u22650.5 IU/mL", 
                "safety_issue": "No", 
                "time_frame": "28 days after last active vaccination"
            }, 
            {
                "description": "Non-inferiority of the immune response to JE +Rabies accelerated schedule versus JE vaccine as per conventional schedule", 
                "measure": "Percentage of subjects with PRNT50 \u2265 1:10", 
                "safety_issue": "No", 
                "time_frame": "7 days after last active vaccination"
            }, 
            {
                "description": "Kinetics of antibody response for Rabies on Days 1, 8, 15, 36, 57, 91, 181 and 366.", 
                "measure": "Percentage of subjects with RVNA titer \u2265 0.5 IU/mL and RVNA Geometric Mean Titer", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 8, 15, 36, 57, 91, 181 and 366"
            }, 
            {
                "description": "Kinetics of antibody response for JE on Days1, 15, 22, 36, 57, 91, 181 and Day 366", 
                "measure": "Percentage of subjects with PRNT50 \u2265 1:10 and PRNT50 Geometric Mean Titer", 
                "safety_issue": "No", 
                "time_frame": "Days1, 15, 22, 36, 57, 91, 181 and Day 366"
            }, 
            {
                "measure": "Proportion of subjects with solicited local reactions", 
                "safety_issue": "Yes", 
                "time_frame": "7 days following each vaccination."
            }, 
            {
                "measure": "Proportion of subjects with solicited systemic and other reactions", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 (postvaccination) through Day 14 (inclusive) and Day 29 through Day 35 (inclusive)."
            }, 
            {
                "measure": "Number of subjects with all AEs (including SAEs and AEs leading to subject withdrawal)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 (postvaccination) through Day 57 (upon completion of clinic visit)."
            }, 
            {
                "measure": "Number of subjects with all vaccine related SAEs", 
                "safety_issue": "Yes", 
                "time_frame": "Day 57 (post completion of clinic visit) through Day 366 (or study termination)."
            }, 
            {
                "measure": "Number of subjects with all concomitant medications", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 through Day 57"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Vaccines", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}